Bayer (BAYN) Given a €124.00 Price Target at Commerzbank

Bayer (FRA:BAYN) received a €124.00 ($147.62) price objective from Commerzbank in a report issued on Tuesday. The firm presently has a “buy” rating on the healthcare company’s stock. Commerzbank’s price target would suggest a potential upside of 14.94% from the stock’s current price.

BAYN has been the topic of a number of other research reports. Nord/LB restated a “neutral” rating on shares of Bayer in a research report on Wednesday, December 27th. Barclays set a €105.00 ($125.00) price target on Bayer and gave the company a “sell” rating in a research report on Monday, November 6th. DZ Bank reiterated a “buy” rating on shares of Bayer in a research report on Monday, December 11th. Baader Bank set a €120.00 ($142.86) price target on Bayer and gave the company a “neutral” rating in a research report on Wednesday, September 13th. Finally, Independent Research set a €120.00 ($142.86) price target on Bayer and gave the company a “neutral” rating in a research report on Tuesday, November 28th. One investment analyst has rated the stock with a sell rating, seven have assigned a hold rating and fourteen have assigned a buy rating to the company. Bayer currently has an average rating of “Buy” and an average target price of €122.33 ($145.63).

Shares of Bayer (FRA:BAYN) opened at €107.88 ($128.43) on Tuesday. The firm has a market capitalization of $89,050.00 and a price-to-earnings ratio of 28.92. Bayer has a 52-week low of €99.69 ($118.68) and a 52-week high of €123.82 ($147.40).

TRADEMARK VIOLATION WARNING: This piece of content was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this piece of content on another site, it was illegally copied and reposted in violation of U.S. and international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.com-unik.info/2018/01/09/bayer-bayn-given-a-124-00-price-target-at-commerzbank.html.

About Bayer

Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women’s health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.

Analyst Recommendations for Bayer (FRA:BAYN)

Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit